Header Logo

Connection

Mark Pollack to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Treatment Outcome.
Mark Pollack
Connection Strength
2.321
Treatment Outcome
  1. Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety. 2013 Nov; 30(11):1114-20.
    View in: PubMed
    Score: 0.248
  2. Examining Insomnia During Intensive Treatment for Veterans with Posttraumatic Stress Disorder: Does it Improve and Does it Predict Treatment Outcomes? J Trauma Stress. 2020 08; 33(4):521-527.
    View in: PubMed
    Score: 0.098
  3. A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence. J Psychoactive Drugs. 2014 Nov-Dec; 46(5):402-11.
    View in: PubMed
    Score: 0.067
  4. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
    View in: PubMed
    Score: 0.064
  5. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012 Jun; 80(3):404-15.
    View in: PubMed
    Score: 0.057
  6. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012; 81(2):87-97.
    View in: PubMed
    Score: 0.056
  7. Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: a pilot study comparing CA-CBT to applied muscle relaxation. Behav Res Ther. 2011 Apr; 49(4):275-80.
    View in: PubMed
    Score: 0.052
  8. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010 Jul; 15(7):367-73.
    View in: PubMed
    Score: 0.050
  9. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009 Nov; 70(11):1563-70.
    View in: PubMed
    Score: 0.047
  10. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008 Jun; 28(3):308-16.
    View in: PubMed
    Score: 0.043
  11. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008 Oct; 42(14):1176-84.
    View in: PubMed
    Score: 0.043
  12. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
    View in: PubMed
    Score: 0.042
  13. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry. 2007 Jul; 68(7):1010-3.
    View in: PubMed
    Score: 0.041
  14. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
    View in: PubMed
    Score: 0.040
  15. Attending to emotional cues for drug abuse: bridging the gap between clinic and home behaviors. Sci Pract Perspect. 2007 Apr; 3(2):48-56.
    View in: PubMed
    Score: 0.040
  16. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007 Feb; 27(1):85-8.
    View in: PubMed
    Score: 0.039
  17. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
    View in: PubMed
    Score: 0.039
  18. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
    View in: PubMed
    Score: 0.037
  19. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006; 23(6):373-6.
    View in: PubMed
    Score: 0.037
  20. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov; 66(11):1401-8.
    View in: PubMed
    Score: 0.036
  21. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005 Jan; 20(1):9-11.
    View in: PubMed
    Score: 0.034
  22. The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005; 66 Suppl 4:23-7.
    View in: PubMed
    Score: 0.034
  23. CBT for Vietnamese refugees with treatment-resistant PTSD and panic attacks: a pilot study. J Trauma Stress. 2004 Oct; 17(5):429-33.
    View in: PubMed
    Score: 0.033
  24. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004 Sep; 65(9):1219-22.
    View in: PubMed
    Score: 0.033
  25. Changes in anxiety sensitivity with pharmacotherapy for panic disorder. J Psychiatr Res. 2004 Sep-Oct; 38(5):491-5.
    View in: PubMed
    Score: 0.033
  26. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
    View in: PubMed
    Score: 0.033
  27. Unmet needs in the treatment of anxiety disorders. Psychopharmacol Bull. 2004; 38(1):31-7.
    View in: PubMed
    Score: 0.032
  28. What good are positive emotions for treatment? A replication test of whether trait positive emotionality predicts response to exposure therapy for social anxiety disorder. Behav Res Ther. 2023 12; 171:104436.
    View in: PubMed
    Score: 0.031
  29. Using pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT. J Psychiatr Res. 2023 08; 164:357-363.
    View in: PubMed
    Score: 0.031
  30. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003 Jun; 23(3):250-9.
    View in: PubMed
    Score: 0.031
  31. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003; 64 Suppl 15:40-5.
    View in: PubMed
    Score: 0.030
  32. A novel cognitive-behavioral approach for treatment-resistant drug dependence. J Subst Abuse Treat. 2002 Dec; 23(4):335-42.
    View in: PubMed
    Score: 0.029
  33. Abnormal intestinal milieu in posttraumatic stress disorder is not impacted by treatment that improves symptoms. Am J Physiol Gastrointest Liver Physiol. 2022 08 01; 323(2):G61-G70.
    View in: PubMed
    Score: 0.028
  34. New advances in the management of anxiety disorders. Psychopharmacol Bull. 2002; 36(4):79-94.
    View in: PubMed
    Score: 0.028
  35. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001 Dec; 158(12):1989-92.
    View in: PubMed
    Score: 0.028
  36. Sleep quality and outcome of exposure therapy in adults with social anxiety disorder. Depress Anxiety. 2021 11; 38(11):1182-1190.
    View in: PubMed
    Score: 0.027
  37. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May; 62(5):350-7.
    View in: PubMed
    Score: 0.026
  38. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 2001; 62 Suppl 12:24-9.
    View in: PubMed
    Score: 0.026
  39. New developments in panic disorder. Curr Psychiatry Rep. 2000 Aug; 2(4):353-7.
    View in: PubMed
    Score: 0.025
  40. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
    View in: PubMed
    Score: 0.024
  41. A placebo-controlled pilot study of a wearable morning bright light treatment for probable PTSD. Depress Anxiety. 2019 07; 36(7):617-624.
    View in: PubMed
    Score: 0.023
  42. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998 Nov; 55(11):1010-6.
    View in: PubMed
    Score: 0.022
  43. Rate of improvement during cognitive-behavioral group treatment for panic disorder. Behav Res Ther. 1998 Jul-Aug; 36(7-8):665-73.
    View in: PubMed
    Score: 0.022
  44. Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998; 8(3):131-3.
    View in: PubMed
    Score: 0.021
  45. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry. 1997 Dec; 9(4):241-5.
    View in: PubMed
    Score: 0.021
  46. Does d-cycloserine facilitate the effects of homework compliance on social anxiety symptom reduction? J Anxiety Disord. 2018 01; 53:85-90.
    View in: PubMed
    Score: 0.021
  47. Effects of mindfulness meditation on occupational functioning and health care utilization in individuals with anxiety. J Psychosom Res. 2017 04; 95:7-11.
    View in: PubMed
    Score: 0.020
  48. Long-term course and outcome of panic disorder. J Clin Psychiatry. 1997; 58 Suppl 2:57-60.
    View in: PubMed
    Score: 0.020
  49. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997; 58 Suppl 11:19-23.
    View in: PubMed
    Score: 0.020
  50. RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER. Depress Anxiety. 2016 08; 33(8):737-45.
    View in: PubMed
    Score: 0.019
  51. Treatment of dysphoric mania with nefazodone. Am J Psychiatry. 1996 May; 153(5):732-3.
    View in: PubMed
    Score: 0.019
  52. The desire to belong: Social identification as a predictor of treatment outcome in social anxiety disorder. Behav Res Ther. 2016 06; 81:21-34.
    View in: PubMed
    Score: 0.019
  53. The longitudinal course and outcome of panic disorder. Psychiatr Clin North Am. 1995 Dec; 18(4):785-801.
    View in: PubMed
    Score: 0.018
  54. Brain connectomics predict response to treatment in social anxiety disorder. Mol Psychiatry. 2016 May; 21(5):680-5.
    View in: PubMed
    Score: 0.018
  55. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994 May; 55(5):200-5.
    View in: PubMed
    Score: 0.016
  56. Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord. 1994 Apr; 30(4):273-81.
    View in: PubMed
    Score: 0.016
  57. Influence of RGS2 on sertraline treatment for social anxiety disorder. Neuropsychopharmacology. 2014 May; 39(6):1340-6.
    View in: PubMed
    Score: 0.016
  58. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013 Jan; 70(1):87-97.
    View in: PubMed
    Score: 0.015
  59. Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res. 2013 Feb; 47(2):168-74.
    View in: PubMed
    Score: 0.015
  60. Mechanisms of efficacy of CBT for Cambodian refugees with PTSD: improvement in emotion regulation and orthostatic blood pressure response. CNS Neurosci Ther. 2009; 15(3):255-63.
    View in: PubMed
    Score: 0.011
  61. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008 Jun; 13(6):522-7.
    View in: PubMed
    Score: 0.011
  62. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.011
  63. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anxiety. 2008; 25(2):167-71.
    View in: PubMed
    Score: 0.010
  64. Complicated grief: a case series using escitalopram. Am J Psychiatry. 2007 Nov; 164(11):1760-1.
    View in: PubMed
    Score: 0.010
  65. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin. 2007 Jun; 23(6):1431-43.
    View in: PubMed
    Score: 0.010
  66. Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann Clin Psychiatry. 2006 Jan-Mar; 18(1):33-42.
    View in: PubMed
    Score: 0.009
  67. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 Sep; 62(9):1022-30.
    View in: PubMed
    Score: 0.009
  68. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry. 2005 Jun; 66(6):730-5; quiz 808-9.
    View in: PubMed
    Score: 0.009
  69. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004 Oct; 24(5):512-20.
    View in: PubMed
    Score: 0.008
  70. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003 May; 18(3):169-72.
    View in: PubMed
    Score: 0.008
  71. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8.
    View in: PubMed
    Score: 0.008
  72. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001 Oct; 104(4):289-98.
    View in: PubMed
    Score: 0.007
  73. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety. 2001; 13(4):166-78.
    View in: PubMed
    Score: 0.006
  74. Empirically supported treatments for panic disorder: costs, benefits, and stepped care. J Consult Clin Psychol. 2000 Aug; 68(4):556-63.
    View in: PubMed
    Score: 0.006
  75. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun; 157(6):968-74.
    View in: PubMed
    Score: 0.006
  76. Is placebo response the same as drug response in panic disorder? Am J Psychiatry. 2000 Jun; 157(6):1014-6.
    View in: PubMed
    Score: 0.006
  77. Clinician response to treatment refractory panic disorder: a survey of psychiatrists. J Nerv Ment Dis. 1999 Dec; 187(12):755-7.
    View in: PubMed
    Score: 0.006
  78. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999 May; 156(5):756-60.
    View in: PubMed
    Score: 0.006
  79. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. 1999 Mar; 174:213-8.
    View in: PubMed
    Score: 0.006
  80. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998 Nov; 155(11):1570-7.
    View in: PubMed
    Score: 0.006
  81. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull. 1998; 34(2):199-205.
    View in: PubMed
    Score: 0.005
  82. Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry. 1996; 57 Suppl 10:44-8; discussion 49-50.
    View in: PubMed
    Score: 0.005
  83. Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety. 1996-1997; 4(5):240-2.
    View in: PubMed
    Score: 0.005
  84. Pattern of placebo response in panic disorder. Psychopharmacol Bull. 1995; 31(2):273-8.
    View in: PubMed
    Score: 0.004
  85. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry. 1993 Oct; 150(10):1485-90.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.